Request Legal Help Now - Free
LAWSUITS NEWS & LEGAL INFORMATION

Bayer Facing Lawsuits over Xarelto Bleeding Events

Were you looking for Xarelto Blood Thinner Side Effects lawsuits?


Los Angeles, CA: Bayer AG and Janssen, the makers of Xarelto (Rivaroxaban) EI, are facing a wrongful death lawsuit recently filed by the family of a man who suffered irreversible brain bleeding allegedly as a side effect of taking the blood thinner: he died shortly thereafter.

Xarelto is a new generation anticoagulant that is being linked to an increasing number of similar bleeding events, which, in some cases, have allegedly resulted in severe and often fatal injuries from uncontrolled hemorrhaging.

According to this latest lawsuit, the deceased man was prescribed Xarelto in July 2012 for treatment of atrial fibrulation, however, after using the medication for less than 10 days he suffered a fatal bleeding event and passed away on August 1, 2012.

Xarelto is part of a class of drugs known as direct thrombin inhibitors, which are used to reduce the risk of blood clots and strokes. The medication was jointly developed by Bayer and Janssen, and became available in 2011.

Xarelto is marketed as being easier to use than warfarin, which requires blood monitoring during treatment. However, Bayer and Janssen allegedly withheld the fact that currently there is no antidote for the agent, unlike warfarin, where doctors can quickly reverse the blood thinning effects of the medication if hemorrhaging occurs.

According to this latest lawsuit, "As part of their marketing of Xarelto, Defendants widely disseminated direct-to-consumer advertising campaigns that were designed to influence patients, including Decedent, to make inquiries to their prescribing physician about Xarelto and/or request prescriptions for Xarelto,"the complaint filed by McGowen states. "In the course of these direct-to-consumer advertisements, Defendants overstated the efficacy of Xarelto with respect to preventing stroke and systematic embolism, failed to adequately disclose to patients that there is no drug, agent, or means to reverse the anticoagulation effects of Xarelto, and that such irreversibility could have permanently disabling, life-threatening and fatal consequences."

The FDA cited Bayer and Janssen on June 6, 2013, for putting out promotional material for Xarelto that was false or misleading because it minimized the risks associated with the drug.



Legal Help

If you or a loved one has suffered similar damages or injuries, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Last updated on

XARELTO BLEEDING EVENTS LAWSUITS LEGAL ARTICLES AND INTERVIEWS

Xarelto Settlement of $775 million Over Failure to Warn Claims
Xarelto Settlement of $775 million Over Failure to Warn Claims
April 9, 2019
New Orleans: Thousands of patients who took Xarelto have settled, through multi-district litigation, with Johnson & Johnson and Bayer for three quarters of a billion dollars. Plaintiffs allege that the manufacturers marketed the drug to physicians to prevent blood clots, but failed to inform them of Xarelto side effects, which could cause life-threatening complications such as internal bleeding, stroke and death READ MORE

First Xarelto Trial Stalled Over Allegations of Witness Tampering
First Xarelto Trial Stalled Over Allegations of Witness Tampering
November 6, 2017
Philadelphia, PA: Allegations of witness tampering have stalled the beginning of the Xarelto litigation. The first Xarelto trail was set to being Monday, November 6, but instead got sidelined by attempts to determine the significance of a meeting between a key witness, Dr. Timothy Aldridge, the plaintiff’s treating physician, and a Janssen sales representative READ MORE

Xarelto Seeking FDA Approval for Lower Dosage While Litigation Posturing Continues
Xarelto Seeking FDA Approval for Lower Dosage While Litigation Posturing Continues
August 5, 2017
Washington, DC: Towards the end of May plaintiffs embroiled in some 18,000 Xarelto lawsuits consolidated in multidistrict litigation were pushing back against a move by defendants Janssen Pharmaceuticals Inc. (Janssen, a division of Johnson & Johnson) and Bayer HealthCare Pharmaceuticals Inc. (Bayer) to escape claims that relied on allegations plaintiffs had previously dropped READ MORE

ADD YOUR COMMENT ON THIS ISSUE

Fields marked * are mandatory. Please read our comment guidelines before posting.

*Name:

Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.
*Your Comment:

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.
Request Legal Help Now! - Free